- Active not recruitingPHASE3
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
This study is investigating a new medication called Retatrutide for people living with obesity. It aims to see how well this medication helps people maintain their weight loss over a long period.
For: ObesityUnited States · Canada · United Kingdom - Active not recruitingPHASE3
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
This study looks at whether a new medicine, retatrutide, can help adults with obesity who also have heart disease or kidney problems. It aims to see if the medicine can reduce serious heart issues or stop kidney problems from getting worse.
For: Atherosclerotic Cardiovascular Disease (ASCVD) · Chronic Kidney Disease (CKD)United States · Argentina · Australia - RecruitingPHASE3
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
This study looks at new medicines, retatrutide and tirzepatide, for adults with a type of fatty liver disease called MASLD. It aims to see if these drugs can help prevent serious liver problems. Some participants will receive a dummy drug (placebo) to compare.
For: Metabolic Dysfunction-Associated Steatotic Liver DiseaseUnited States · Argentina · Australia - Active not recruitingPHASE3
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
This study looks at a new medicine called Retatrutide for people with Type 2 Diabetes and kidney problems. It checks if the medicine improves blood sugar control and is safe, compared to a dummy medicine, for those already on insulin.
For: Type 2 DiabetesUnited States · Argentina · Brazil - Ongoing, recruitingTherapeutic confirmatory (Phase III)
J1I-MC-GZBK: A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants with Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled Trial (TRIUMPH-2)
This study is looking into a new weekly injection called Retatrutide. It's for people with type 2 diabetes who are also overweight or obese. The main goal is to see how well it helps with weight loss compared to a dummy injection (placebo).
For: Type 2 Diabetes · Obesity · OverweightSpain · Romania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
J1I-MC-GZBM: A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants with Severe Obesity and Established Cardiovascular Disease (TRIUMPH-3)
This study is looking into a new weekly injection called Retatrutide. We want to see if it helps people with severe obesity and heart problems lose weight safely. It's compared to a dummy injection to see how well it works.
For: Obesity · Cardiovascular DiseaseSlovakia · Hungary · Spain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
J1I-MC-GZBN:A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants who have Obesity or Overweight and Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Trial
This study looks at a new weekly injection called LY3437943 to see if it helps people with knee osteoarthritis who are also overweight or obese. It aims to reduce knee pain and body weight, comparing the new drug to a dummy injection.
For: Overweight · Osteoarthritis · KneeSpain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
J1I-MC-GZBJ: A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1); J1I-MC-GOA1: Indication-Specific Appendix (ISA2) for participants with knee osteoarthritis (OA)
This study is looking at a new medicine called Retatrutide for adults who are overweight or have obesity. It also specifically looks at people with knee arthritis. The main goals are to see how much it helps with weight loss and how well it reduces knee pain.
For: Obesity · Overweight · OsteoarthritisRomania · Poland · Hungary - Ongoing, recruitingTherapeutic exploratory (Phase II)
J1I-MC-GZBU - A Phase 2b, Double-Blind Study to Investigate the Effect of LY3437943 on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
This study is looking at a new medicine called LY3437943 for people who are overweight or obese and have long-term kidney disease, whether or not they also have type 2 diabetes. We want to see if this medicine can help improve how well their kidneys work.
For: Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesSpain · Italy - Active not recruitingPHASE3
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
This study is looking into a new medication called retatrutide for people who are overweight or have obesity. It aims to see how well it helps with weight loss and if it's safe, compared to a dummy treatment.
For: Obesity · OverweightUnited States · United Kingdom - Ongoing, recruitingTherapeutic confirmatory (Phase III)
J1I-MC-GZQD: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain (TRIUMPH-7)
This study is looking at a new medicine called Retatrutide for people who are overweight or have obesity and suffer from ongoing lower back pain. It compares the new medicine to a dummy treatment (placebo) to see if it helps with pain and weight over 72 weeks.
For: Overweight · Chronic Low Back Pain (CLBP) · ObesityPoland